Abstract:Zachary Boswell, 1 Jacopo Umberto Verga, 1, 2 James Mackle, 1 Karen Guerrero-Vazquez, 2 Olivier P Thomas, 3 James Cray, 4 Bethany J Wolf, 5 Yeun-Mun Choo, 6 Peter Croot, 7 Mark T Hamann, 8 Gary Hardiman 1, 5, 9 1 School of Biological Sciences and Institute for Global Security, Queen's University, Belfast, Northern Ireland, UK; 2 Genomic Data Science, University of Galway, Galway, Ireland; 3 School of Biological and Chemical Sciences, Ryan Institute, University of Galway, Galway, H91TK33 Ireland; 4 Department of Biomedical Education and Anatomy, College of Medicine and Division of Biosciences, College of Dentistry, Ohio State University, Columbus, OH, USA; 5 Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA; 6 Department of Chemistry, University of Malaya, Kuala Lumpur, Malaysia; 7 Irish Centre for Research in Applied Geoscience, Earth and Ocean Sciences and Ryan Institute, School of Natural Sciences, University of Galway, Galway, Ireland; 8 Departments of Drug Discovery and Biomedical Sciences and Public Health, Colleges of Pharmacy and Medicine, Medical University of South Carolina, Charleston, SC, USA; 9 Department of Medicine, Medical University of South Carolina, Charleston, SC, USA Correspondence: Gary Hardiman, School of Biological Sciences and Institute for Global Food Security, Faculty of Medicine, Health, and Life Sciences, Queen's University Belfast, 19 Chlorine Gardens, Belfast, BT9 5DL, Northern Ireland, UK, Email The urgent need for SARS-CoV-2 controls has led to a reassessment of approaches to identify and develop natural product inhibitors of zoonotic, highly virulent, and rapidly emerging viruses. There are yet no clinically approved broad-spectrum antivirals available for beta-coronaviruses. Discovery pipelines for pan-virus medications against a broad range of betacoronaviruses are therefore a priority. A variety of marine natural product (MNP) small molecules have shown inhibitory activity against viral species. Access to large data caches of small molecule structural information is vital to finding new pharmaceuticals. Increasingly, molecular docking simulations are being used to narrow the space of possibilities and generate drug leads. Combining in-silico methods, augmented by metaheuristic optimization and machine learning (ML) allows the generation of hits from within a virtual MNP library to narrow screens for novel targets against coronaviruses. In this review article, we explore current insights and techniques that can be leveraged to generate broad-spectrum antivirals against betacoronaviruses using in-silico optimization and ML. ML approaches are capable of simultaneously evaluating different features for predicting inhibitory activity. Many also provide a semi-quantitative measure of feature relevance and can guide in selecting a subset of features relevant for inhibition of SARS-CoV-2. Keywords: SARS-CoV-2, natural products, protease, methyl transferases, RNA dependent polymerases, viral transcription, genome replication, betacoronavirus Coronaviruses (CoVs) are a family of viruses that cause lung and intestinal illnesses in humans and animals. Generally, these are mild illnesses characterized by cold-like symptoms. However, viruses that cause severe disease have emerged over the past twenty years, first with the severe acute respiratory syndrome (SARS) epidemic in China in 2002–2003 and subsequently the Middle East respiratory syndrome (MERS) on the Arabian Peninsula in 2012. The novel coronavirus that emerged in Wuhan at the tail end of 2019 has to date killed >6.01 million people (JHU-CSSE, 2022) and collectively cost the world's economy >16 trillion dollars. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative virus responsible for this coronavirus disease (COVID-19). The urgent need to control this family of viruses has led to a reassessment of approaches to identify and new antiviral drugs. One area of investigation has been marine natural products, compounds or substance produced by living organisms present in the marine environment. Access to collections of these natural products is vital to finding new pharmaceuticals to combat coronavirus diseases. Increasingly, advances in artificial intelligence are aiding this drug discovery process. The novel coronavirus that emerged in Wuhan at the tail end of 2019 has to date killed >6.01 million people (JHU-CSSE, 2022) and collectively cost the world's economy >16 trillion dollars. 1 Despite the massive research response to the pandemic, 2 there are yet no clinically approved broad-spectrum -Abstract Truncated-

In silico Study of Antiviral Activity of Polyphenol Compounds from Ocimum basilicum by Molecular Docking, ADMET, and Drug-Likeness Analysis

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Molecular Docking Studies on the Anti-viral Effects of Compounds From Kabasura Kudineer on SARS-CoV-2 3CLpro

Identification of Drug Combination Therapies for SARS-CoV-2: A Molecular Dynamics Simulations Approach

Computational screening of natural compounds from Salvia plebeia R. Br. for inhibition of SARS-CoV-2 main protease

Searching possible SARS-CoV-2 main protease inhibitors in constituents from herbal medicines using in silico studies

A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2

Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants – Withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi) – a molecular docking study

In Silico Evaluation of Iranian Medicinal Plant Phytoconstituents as Inhibitors against Main Protease and the Receptor-Binding Domain of SARS-CoV-2

Potential of Plant Bioactive Compounds as SARS-CoV-2 Main Protease (Mpro) and Spike (S) Glycoprotein Inhibitors: A Molecular Docking Study

Evaluation of the Binding Affinity of Anti-Viral Drugs against Main Protease of SARS-CoV-2 Through a Molecular Docking Study

Evaluation of inhibition effect and interaction mechanism of antiviral drugs on main protease of novel coronavirus: molecular docking and molecular dynamics studies

In silico screening of potential inhibitors from Cordyceps species against SARS-CoV-2 main protease

In-Silico Approaches for the Screening and Discovery of Broad-Spectrum Marine Natural Product Antiviral Agents Against Coronaviruses

Systematic investigation of selected bio-molecules, potentially effective in inhibiting SARS-CoV-2/COVID-19 via in-silico analysis

In silico Study on Physicochemical, Pharmacokinetic and Toxicity Profiles of Available Antiviral Drugs and The Drug-Target Interaction with Protease of SARS-CoV-2

Novel Coronavirus (SARS-CoV-2) Main Protease: Molecular docking of Puerarin as a Potential inhibitor

Traditional herbal compounds as candidates to inhibit the SARS-CoV-2 main protease: an in silico study

Flavonol morin targets host ACE2, IMP-α, PARP-1 and viral proteins of SARS-CoV-2, SARS-CoV and MERS-CoV critical for infection and survival: a computational analysis

Phytochemicals from Leucas zeylanica Targeting Main Protease of SARS-CoV-2: Chemical Profiles, Molecular Docking, and Molecular Dynamics Simulations

The coronavirus disease 2019 main protease inhibitor from Andrographis paniculata (Burm. f) Ness